Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Cancer Therapies02:49

Cancer Therapies

Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Anatomical versus non-anatomical liver resection for hepatocellular carcinoma - an international multicenter propensity score-matched analysis of short- and long-term outcomes in an international multicenter cohort.

HPB : the official journal of the International Hepato Pancreato Biliary Association·2026
Same author

Utility of the Iwate Difficulty Scoring System for the Stratification of Laparoscopic Right Hepatectomies: An International Multicenter Study.

Journal of hepato-biliary-pancreatic sciences·2026
Same author

PEPN1924, A Phase II Study of Trastuzumab Deruxtecan in Patients With Recurrent Human Epidermal Growth Factor Receptor 2+ Osteosarcoma: A Children's Oncology Group Pediatric Early-Phase Clinical Trial Network Study.

JCO oncology advances·2026
Same author

An international framework for clinical translation of molecular classifiers in osteosarcoma.

NPJ precision oncology·2026
Same author

Validation of the Southampton Difficulty Scoring System in Robotic Liver Surgery and Development of the International RoboLiver Difficulty Scoring System.

Journal of the American College of Surgeons·2026
Same author

Sociodemographics and Attrition in Children With Osteosarcoma Enrolled in the AOST0331 Clinical Trial.

JAMA network open·2026

Related Experiment Video

Updated: May 18, 2026

Three-Dimensional Bone Extracellular Matrix Model for Osteosarcoma
08:07

Three-Dimensional Bone Extracellular Matrix Model for Osteosarcoma

Published on: April 12, 2019

New targets and approaches in osteosarcoma.

Jonathan Gill1, Manpreet K Ahluwalia, David Geller

  • 1Department of Pediatrics, Montefiore Medical Center and The Children's Hospital at Montefiore, Bronx, NY, United States.

Pharmacology & Therapeutics
|September 18, 2012
PubMed
Summary

Osteosarcoma survival rates have stagnated despite conventional chemotherapy. New drug development is crucial for improving outcomes in bone cancer patients, particularly those with metastatic disease.

More Related Videos

Intratibial Osteosarcoma Cell Injection to Generate Orthotopic Osteosarcoma and Lung Metastasis Mouse Models
04:25

Intratibial Osteosarcoma Cell Injection to Generate Orthotopic Osteosarcoma and Lung Metastasis Mouse Models

Published on: October 28, 2021

Establishment of Cancer Stem Cell Cultures from Human Conventional Osteosarcoma
09:25

Establishment of Cancer Stem Cell Cultures from Human Conventional Osteosarcoma

Published on: October 14, 2016

Related Experiment Videos

Last Updated: May 18, 2026

Three-Dimensional Bone Extracellular Matrix Model for Osteosarcoma
08:07

Three-Dimensional Bone Extracellular Matrix Model for Osteosarcoma

Published on: April 12, 2019

Intratibial Osteosarcoma Cell Injection to Generate Orthotopic Osteosarcoma and Lung Metastasis Mouse Models
04:25

Intratibial Osteosarcoma Cell Injection to Generate Orthotopic Osteosarcoma and Lung Metastasis Mouse Models

Published on: October 28, 2021

Establishment of Cancer Stem Cell Cultures from Human Conventional Osteosarcoma
09:25

Establishment of Cancer Stem Cell Cultures from Human Conventional Osteosarcoma

Published on: October 14, 2016

Area of Science:

  • Oncology
  • Orthopedic Oncology
  • Cancer Therapeutics

Background:

  • Osteosarcoma is the most prevalent primary bone malignancy.
  • Current treatments involving surgery and chemotherapy offer a cure for localized disease in approximately two-thirds of patients.
  • Survival rates for patients with detectable metastases at diagnosis remain poor, with only one-third achieving a cure.

Purpose of the Study:

  • To review the established rationale behind conventional chemotherapy regimens for osteosarcoma.
  • To explore novel therapeutic agents currently under investigation for osteosarcoma treatment.
  • To identify promising future treatment strategies to improve patient survival.

Main Methods:

  • Literature review of conventional osteosarcoma chemotherapy.
  • Analysis of ongoing clinical trials and preclinical research for new osteosarcoma agents.
  • Synthesis of current data and future therapeutic directions.

Main Results:

  • Conventional chemotherapy has shown limited improvement in survival trends over the last two decades.
  • Several novel agents are in various stages of development, showing potential in preclinical and early clinical studies.
  • The need for innovative therapeutic approaches is evident.

Conclusions:

  • There is a critical need for novel therapeutic strategies to overcome the stagnation in osteosarcoma survival rates.
  • Investigating new agents is essential for improving outcomes, especially for patients with metastatic osteosarcoma.
  • Future research should focus on rationally developing and testing new treatments.